Zai Lab (ZLAB) Scheduled to Post Quarterly Earnings on Tuesday

Zai Lab (NASDAQ:ZLAB) is set to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.16). Zai Lab had a negative return on equity of 37.96% and a negative net margin of 92.44%. The business had revenue of $100.50 million during the quarter, compared to the consensus estimate of $94.46 million. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Stock Performance

Shares of NASDAQ:ZLAB opened at $30.89 on Tuesday. Zai Lab has a 1 year low of $13.48 and a 1 year high of $36.60. The stock’s 50-day moving average is $24.26 and its 200 day moving average is $20.24.

Wall Street Analysts Forecast Growth

ZLAB has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Friday, October 25th. JPMorgan Chase & Co. raised their target price on shares of Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research report on Monday, October 21st.

Insider Activity

In related news, insider Joshua L. Smiley sold 4,352 shares of Zai Lab stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $16.67, for a total transaction of $72,547.84. Following the completion of the transaction, the insider now directly owns 43,232 shares of the company’s stock, valued at $720,677.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 13.88% of the stock is currently owned by company insiders.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.